Fox Run Management’s AbCellera Biologics ABCL Stock Holding History

Fox Run Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.7K	Buy	+11,176	New	+$54.6K	0.01%	884
2024 Q2	–	Sell	-31,123	Closed	-$141K	–	739
2024 Q1	$141K	Buy	+31,123	New	+$159K	0.03%	681
2023 Q3	–	Sell	-40,272	Closed	-$260K	–	666
2023 Q2	$260K	Buy	+40,272	New	+$275K	0.07%	497
2022 Q2	–	Sell	-24,366	Closed	-$238K	–	491
2022 Q1	$238K	Buy	+24,366	New	+$231K	0.13%	358

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Fox Run Management's ABCL Position: Q2 2026 in Review

Fox Run Management opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 11,176 shares worth $87.7K. The stake represents 0.01% of the portfolio and ranks #884 among its holdings. This is a return to the name: Fox Run Management previously reported a position in ABCL as recently as Q1 2024.

Fox Run Management first reported a position in ABCL in Q1 2022 and has held it in 4 quarters since. The position peaked at $260K in Q2 2023. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Fox Run Management held 11,176 shares of AbCellera Biologics worth $87.7K as of Q2 2026.
AbCellera Biologics was a new Fox Run Management position in Q2 2026.
AbCellera Biologics made up 0.01% of Fox Run Management's portfolio in Q2 2026, its #884 holding.
Fox Run Management first reported a position in AbCellera Biologics in Q1 2022 and has held it in 4 quarters since.
Fox Run Management's AbCellera Biologics position peaked at $260K in Q2 2023.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.